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ABSTRACT 
The clinical features, course and histology of liver in 20 patients; mostly middle aged to elderly
females, closely resembling chronic Non A Non B hepatitis is presented. They presented quite late in
their disease and therefore, complications such as variceal bleeds, ascites and encephalopathy were
frequent. Our patients were negative for hepatitis B and C virus serology. Metabolic and immune
causes of chronic liver disease were also ruled out. To the best of our knowledge, this is the first study
of its kind elaborating the clinical features, course and histology of liver in chronic Non B Non C
hepatitis and raises a number of questions as to the nature of the infecting virus and the epidemiology
of disease (JPMA 41: 281, 1991).
INTRODUCTION 
Parenterally transmitted viral infections, i.e., hepatitis B, Non A Non B, C and D are well established
causes of chronic hepatitis and cirrhosis in this region. One study from Pakistan showed the prevalence
of hepatitis B related cirrhosis to be just over 60%1. However, a number of patients seen at our
institution have no serological evidence of hepatitis B, C or D or any autoimmune ormetabolib cause of
cirrhosis. Such Non B, Non C chronic liver disease could also be prevalent in other parts of the world.
A recent epidemiological suivey fromJapan showed a prevalence rate of 11.8-13% in Non B, Non C
chronic hepatitis and cirrhosis2. Clinical features, laboratory data, course, histopathology and the
results of various therapeutic modalities employed in the management of this disease are presented in
this series.
PATIENTS AND METHODS 
A total of 100 patients with chronic liver disease attending outpatient clinic or admitted through emer-
gency room at the Aga Than University Hospital over a three months period from August, 1990 were
screened for various causes of chronic liver disease. The following serological tests were done to
screen for hepatitis B virus infection; HBs Ag, HBs Ab, HBc Ab (IgG type), hepatitis delta antibody (in
HBs Ag positive cases only), HBe Ag and HBe Ab. Those patients who were negative for hepatitis B
virus infection were screened for hepatitis C virus infection (enzyme linked immunosorbent assay kits
manufactured by Abbott Laboratories was used. For HCV testing, second generation kit produced by
the same manufacturer was used). Patients who were negative for HCV as well were then screened for
autoimmune chronic liver disease, haemochromatosis, Wilson’s disease and alpha-i antitrypsin
deficiency by measuring anti-smooth muscle, anti-nuclear and anti- mitochondrial antibodies, serum
ferritin levels, serum caeruloplasmin levels and alpha-i antitrypsin assays (serum ferritin was checked
by DPC radioimmunoassay kit manufactured by Diagnostic Products Corporation, Los Angeles, CA
90045. Serum alpha 1 antitrypsin and serum caeruloplasmin assays were done by Nor-Partigen
Immunodiffusion Plates for quantitative protein determination manufactured by Behring). Patients,
who tested negative for all the above mentioned causes of chronic liver disease, were entered into the
study. Patients with a history of parenteral thug abuse, hepatotoxic thug exposure and heavy alcohol
intake were also excluded. Follow up of patients entered into the study was done over a one year
period. Patients were evaluated clinically and the following liver function tests were done regularly, at
least at three monthly intervals; serum biirubin, SGOT, SGPT, alkaline phosphatase, serum albumin,
serum alphafetoprotein and prothrombin time. Abdominal ultrasound to look at liver, spleen, pancreas
and gall bladder were routinely done, at least once. Liver biopsies were done in all, to study the
histological characteristics of this disease. Particular attention was paid to look at complications such as
the development of ascites, portasystemic encephalopathy, spontaneous bacterial peritonitis,
gastrointestinal bleeds and the development of hepatoma. Patients with established decompensated
cirrhosis were treated with salt restriction, diuretics such as spironolactone and frusemide. Treatment of
encephalopathy was done in the standard manner which included correction of fluid and electrolyte
imbalance, protein restriction and lactulose where indicated. Exacerbations of hepatitis were treated
with three courses of recombinant alpha interferon in one patient only.
RESULTS 
Our series of twenty patients with chronic liver disease was picked up because of abnormal liver
function tests or as a result of complications such as decompensated cirrhosis, bleeding esophageal
varices or portasystemic encephalopathy. Seven (35%) patients presented with gastroesophageal
variceal bleed, nine (45%) with decompensated cirrhosis with or without encephalopathy and one with
spontaneous bacterial peritonitis. Three (15%) were diagnosed at cholecystectomy where a liver biopsy
was taken. Five (25%) were males giving a female preponderence of 75%. The age ranged between
seven to seventyone years with a mean of 52.3 years. The peak incidence occurred in the 6th and 7th
decades. Nineteen (95%) patients were urban dwellers. Three (15%) patients had a history of travel
outside the Indian subcontinent and 3 patients had a history of blood transfusions in past. A family
history of liver disease was available in two patients, one patient’s father died of carcinoma of liver and
the other had a sister who had hepatitis at the same time as the patient. Ten (50%) had a past history of
jaundice. On examination majority were well nourished and only nine (45%) had a mild jaundice.
Signs of chronic liver disease such as spider angiomata were present in three (15%) and palmar
erythema in four (20%) patients. Hepatosplenomegaly was present in twelve (60%) patients. Six (30%)
had encephalopathy due to their liver disease. Serum bilirubin ranged between 0.6-6.5 mg/dl (mean 2.1
± SD 1.44 mg/dl). SGOT between 18-596 T.U./L (mean 147± SD 165.3 I.U./L); SGPT 16-248 I.U./L
(mean 114±SD 183.03 I.U./L) and serum alkaline phosphatase 5 1-525 I.U./L (mean 189±161.83 I.U./L
Serum albumin level of less than 208g/dl was observed in fourteen (70%) and hyperglobulinaemia in
twelve (60%) patients. Serum alphafetoprotein level was greater than 363/4/nil in only one patient with
hepatoma. Serum anti-nuclear antibody was positive in three patients in a strength of + +. Serology for
hepatitis B and C was negative in 14, while in 6 patients anti HBc (IgG) was positive. Liver biopsies
were done in all patients. In seventeen patients the biopsies were done by us and tissue was available
for detailed examination. The remaining three liver biopsies were done elsewhere. The histological





The significant clinical manifestations that developed during the follow-up are shown in Table II.
Differences in the clinical features, biochemical profile and auto-antibody screen between our patients
with chronic Non B Non C hepatitis and those of chronic Non A Non B hepatitis described in literature
are presented in Table III.
During follow-up two patients died from complications of porta systemic shunt surgery. One patient
with .hepatoma had local injections of absolute alcohol into the tumour and is doing well. The serum
alpha-feto protein levels have come back to normal and the tumour has shrunk in size considerably on
ultrasonic examination. One patient received interferon therapy for her chronic active hepatitis. She
responded well to this therapy initially but later became refractory to this form of treatment and
developed porta systemic encephalopathy and esophageal variceal haemorrhage. She is awaiting liver
transplantation. One patient who has had liver transplant, a young man, banker by profession is doing
well and his liver function tests are within normal limits one year after liver transplant.
DISCUSSION 
Non A Non B hepatitis is a well recognized and important cause of chronic liver disease3. Worldwide
Non A Non B hepatitis seems to represent 15 to 25% of clinical cases of viral hepatitis4. One of the
agents thought to be responsible for Non A Non B hepatitis has been cloned and sequenced in 19895
and has been termed hepatitis C virus. This and the subsequent development of an ELISA antibody
tests6 have been major break throughs in the study of Non A Non B hepatitis. However, as more and
more patients with chronic Non A Non B hepatitis are tested for anti-HCV with this ELISA test, it has
become clear that a proportion of these patients tested negative for HCV C100-3 antibody. Serological
evidence for HCV infection can be detected in 60 to 84% of post-transfusion chronic Non A Non B
hepatitis and approximately 58% cases of sporadic or “community acquired” chronic Non A Non B
hepatitis6-8. We have described a series of twenty patients presenting to our hospital with chronic liver
disease in which serology for hepatitis B and C was negative. Except the three patients with a history of
blood transfusions, all patients would be categorized as having sporadic Non A Non B hepatitis. This
observation concurs with data from the Centre for Disease Control Atlanta which shows that only upto
10% of the reported patients with Non A Non B hepatitis have a history of blood transfusion and that in
at least 40% of patients there is no known source of infection9. The clinical profile of our patients
resembled that of patients with Non A Non B chronic hepatitis, in particular the sporadic variety10. The
infection is frequently asymptomatic and anicteric. Most prominent symptom is mild fatigue and
stigmata of chronic liver disease are rare11. The elevation in serum transaminases is generally mild and
there is waxing and vaning pattern of activity during follow-up, a pattern usually seen in chronic Non A
Non B hepatitis1. However, our patients presented quite late in the course of their disease and
complications of portal hypertension such as variceal bleeds and ascites seemed to be setting in.
Spontaneous bacterial peritonitis and encephalopathy were also frequent symptoms. The development
of hepatoma also suggests that the disease had been present for quite a while and gone unnoticed. The
female preponderance (75%) of the disease is noteworthy. This and antinuclear antibody positivity in
three patients could mean a chronic lupoid type of reaction induced by the infecting virus in the liver in
some patients. False positive serological test for hepatitis C virus in patients suffering from
autoimmune chronic active hepatitis has been reported12. The histological features of liver show
cirrhosis with varying degrees of chronic active hepatitis in fourteen (82%) out of seventeen patients,
chronic active hepatitis without cirrhosis in two and hepatoma in one patient with a well established
cirrhosis. Histological features of chronic Non A Non B hepatitis as described by Sherlock13 include
the occurrence of fatty change, kupifer cell hyperplasia, the presence of lymph follicle aggregates in
portal tracts, a disproportionate degree of sinusoidal cellular infiltration occasional damage to bile duct
epithelium and the absence of ground glass cells. Most of these features were present in the majority of
our patients. Negative stain for hepatitis B surface antigen (Shikata) in all the seventeen liver biopsy
specimens is also noteworthy. Many possible explanations have been advanced for the absence of anti
HCV in our patients diagnosed as Non B Non C chronic hepatitis. Firstly, that the disease may be of a
nonviral origin. This seems unlikely as the nonviral causes of chronic liver disease were excluded as far
as possible. Secondly that the sensitivity of the HCV assay may be less than optimal. We used the
second generation of HCV antibody test which tests for not one but two epitopes on the C100-3 part of
HCV antigen. Thirdly, that there may be inadequate sampling for anti HCV, particularly the absence of
late sampling. The great majority of our patients presented quite late in the course of their disease as
evidenced by the presence of chronic hepatitis and cirrhosis on liver biopsy and therefore this
explanation seems unlikely. However, serial testing of these patients for HCV antibody is underway.
Lastly, is the possibility that there exists another Non A Non B hepatitis agent. This has been suggested
by the occurrence of multiple episodes of Non A Non B hepatitis in a single patient14, by cross
challenge studies in the chimpanzee15 and by inactivation studies that distinguished chloroform
sensitive hepatitis agent and a chloroform insensitive16 agent by testing the sera and liver biopsy
specimens of these patients for hepatitis C RNA polymerase chain reaction, for HBV DNA to detect
evidence of hepatitis B infection and animal inoculation of sera from these patients. The transient
response of disease in one patient to recombinant alpha interferon therapy requires further evaluation in
controlled trials. The absence of known risk factors for the development of chronic hepatitis and denial
of a history of blood transfusions/parenteral drug use in the vast majority (85%) of our patients brings
to one’s mind the possibility of other modes of transmission of infection, which could either be sexual
or be arthropod borne or be passed on via the orofecal route. This could be a significant problem in the
community and needs to be evaluated further.
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